US House Appropriators Keep A Bullseye On FDA’s CBD Regulation Development
Executive Summary
Appropriations subcommittee notes the funding in summary of its draft budget bill. Language on FDA’s development of CBD regulatory framework will be included in panel’s report to be released 24 hours before full committee’s markup.
You may also be interested in...
Congress Boosts FDA Food Safety Budget Nearly $700M, Orders Reports On Formula Supply
Appropriators are “concerned by the fragility of the infant formula supply chain and the detrimental health impacts that can arise from shortage of these regulated products.” Their report published with FY2023 omnibus appropriations also asks for list of Russian firms with pending NDAs, including OTCs.
VMS Market Regulation Gets Targeted Funding In US FDA Budget; OTC Switches Get Question
In report explaining congressional intent for omnibus spending bill, House and Senate appropriators note concerns about, and target $5m for, regulation of supplement market. Question on moving drug ingredients from Rx to nonprescription not accompanied by targeted funding.
US FDA's Consumer Health Oversight Absent From Appropriators’ Request For COVID-19 Assessment
House appropriators don’t mention the consumer health market in requesting a report on FDA’s response to COVID-19, but the agency’s frequent warnings about products marketed with unlawful claims could merit mentioning. Encouraging accelerated production of hand sanitizers while also ensuring the additional supplies are safe is another component of its COVID-19 response that could be covered in an assessment of its response to the pandemic.